Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection ; volume:13 ; number:1 ; day:13 ; month:10 ; year:2022 ; pages:1 ; date:12.2022
Nature Communications ; 13, Heft 1 (13.10.2022), 1, 12.2022
- Klassifikation
-
Recht
- Urheber
-
Khan, Khadija
Karim, Farina
Ganga, Yashica
Bernstein, Mallory
Jule, Zesuliwe
Reedoy, Kajal
Cele, Sandile
Lustig, Gila
Amoako, Daniel
Wolter, Nicole
Samsunder, Natasha
Sivro, Aida
San, James Emmanuel
Giandhari, Jennifer
Tegally, Houriiyah
Pillay, Sureshnee
Naidoo, Yeshnee
Mazibuko, Matilda
Miya, Yoliswa
Ngcobo, Nokuthula
Manickchund, Nithendra
Magula, Nombulelo
Karim, Quarraisha Abdool
Gottberg, Anne von
Abdool Karim, Salim S.
Hanekom, Willem
Gosnell, Bernadett I.
Lessells, Richard J.
Oliveira, Tulio de
Moosa, Mahomed-Yunus S.
Sigal, Alex
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-33371-0
- URN
-
urn:nbn:de:101:1-2022123021175434086542
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Khan, Khadija
- Karim, Farina
- Ganga, Yashica
- Bernstein, Mallory
- Jule, Zesuliwe
- Reedoy, Kajal
- Cele, Sandile
- Lustig, Gila
- Amoako, Daniel
- Wolter, Nicole
- Samsunder, Natasha
- Sivro, Aida
- San, James Emmanuel
- Giandhari, Jennifer
- Tegally, Houriiyah
- Pillay, Sureshnee
- Naidoo, Yeshnee
- Mazibuko, Matilda
- Miya, Yoliswa
- Ngcobo, Nokuthula
- Manickchund, Nithendra
- Magula, Nombulelo
- Karim, Quarraisha Abdool
- Gottberg, Anne von
- Abdool Karim, Salim S.
- Hanekom, Willem
- Gosnell, Bernadett I.
- Lessells, Richard J.
- Oliveira, Tulio de
- Moosa, Mahomed-Yunus S.
- Sigal, Alex
- SpringerLink (Online service)
Ähnliche Objekte (12)
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease